within Pharmacolibrary.Drugs.ATC.L;

model L01FX08
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.866666666666666e-06,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00524,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00373,
    k12             = 0.494,
    k21             = 0.494
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01FX08</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Elotuzumab is a humanized IgG1 monoclonal antibody targeting SLAMF7, used in the treatment of multiple myeloma in combination with other agents. It is FDA-approved for relapsed or refractory multiple myeloma in adult patients.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics from adult patients with relapsed or refractory multiple myeloma, population PK estimated after intravenous administration.</p><h4>References</h4><ol><li><p>Ide, T, et al., &amp; Vezina, HE (2021). Model-Based Determination of Elotuzumab Pharmacokinetics in Japanese Patients With Multiple Myeloma Incorporating Time-Varying M Protein. <i>Journal of clinical pharmacology</i> 61(1) 64–73. DOI:<a href=\"https://doi.org/10.1002/jcph.1698\">10.1002/jcph.1698</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32656777/\">https://pubmed.ncbi.nlm.nih.gov/32656777</a></p></li><li><p>Ghai, A, et al., &amp; Achilefu, S (2021). Development of [. <i>European journal of nuclear medicine and molecular imaging</i> 48(5) 1302–1311. DOI:<a href=\"https://doi.org/10.1007/s00259-020-05097-y\">10.1007/s00259-020-05097-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33179150/\">https://pubmed.ncbi.nlm.nih.gov/33179150</a></p></li><li><p>Iida, S, et al., &amp; Chou, T (2017). Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study. <i>International journal of hematology</i> 105(3) 326–334. DOI:<a href=\"https://doi.org/10.1007/s12185-016-2138-4\">10.1007/s12185-016-2138-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27848182/\">https://pubmed.ncbi.nlm.nih.gov/27848182</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01FX08;
